FDA clears five Zepbound labeling supplements on the same day

On October 18, 2024, the FDA acted on five labeling supplements for Zepbound (tirzepatide) at once, including one recorded as an efficacy labeling change backed by clinical data, according to the agency's approval record for the drug ^[1]. All five fall under New Drug Application 217806, held by Eli Lilly and Co. ^[1]

The five supplements are S-005, S-006, S-011, S-015 and S-019. They carry different categories in the FDA's supplement table: S-006 is listed as "Efficacy-Labeling Change With Clinical Data," S-005, S-011 and S-015 are listed as package insert and/or medication guide changes, and S-019 is listed as a medication guide and package insert change ^[1]. The record links all five to the same label file dated October 18, 2024, so the practical result is one combined update to the prescribing information and the patient medication guide rather than five separate documents ^[1].

What the FDA record does not include is the name of the trial behind the efficacy change, what that trial measured, the results, or the specific wording that changed in the label ^[1]. The entry for these supplements lists a label and an action letter, with no review document posted alongside them ^[1]. Those details have not been disclosed in the record.

Zepbound's active ingredient is tirzepatide. The FDA product table for the same application lists 24 Zepbound presentations, all prescription-only and all flagged as reference listed drug and reference standard, with no therapeutic equivalence code assigned ^[1]. Those entries cover single-dose strengths from 2.5 mg/0.5 mL through 15 mg/0.5 mL and multi-dose strengths from 10 mg/2.4 mL (4.17 mg/mL) through 60 mg/2.4 mL (25 mg/mL), plus presentations labeled "Zepbound (autoinjector)" and "Zepbound KwikPen" ^[1]. Zepbound was first approved on November 8, 2023, under priority review ^[1].

FDA uses a separate category, "Efficacy-New Indication," for approvals that add a new use to a drug's label ^[1]. The October 18 supplements were not recorded under that category, and none of the five is categorized as a safety-related labeling change ^[1]. Whether the new clinical data strengthened an existing claim, added one, or replaced earlier figures has not been reported in the record ^[1].

Why it matters for patients

A package insert and medication guide update changes the paperwork patients receive with a prescription and the reference material clinicians consult. For people taking Zepbound, or comparing it with semaglutide products such as Ozempic, Wegovy and Rybelsus, the label is where FDA-reviewed weight-loss and other trial results are stated. An efficacy change with clinical data means trial results were part of what the agency reviewed, but the record does not show what those results were or how the label now reads ^[1].

That gap matters because label numbers are often cited when patients and clinicians compare options across this drug class, and because medication guides are handed out at the pharmacy with each fill. A patient who receives a revised guide with a Zepbound prescription has no public description of the change posted with this record ^[1].

It also matters what the action was not. Nothing in the record indicates the October 18 supplements added an approved use or introduced a new safety warning; the five are grouped under efficacy and general labeling categories only ^[1]. The trial behind the efficacy change, and what it found, has not been reported ^[1].